Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 284 participants.

Also called NCT01252810

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose diagnostic
Phase
Phase 2
Enrolled
  • 284 participants (enrolled count) (from the registry)
Sponsor
  • GE Healthcare Registry lists this organization as the lead sponsor
  • Medpace, Inc. Registry lists this organization as a collaborator
Registry
  • NCT NCT01252810
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01252810. Randomized; double masking; primary purpose diagnostic. Start 2010-11 (registry gives no type); primary completion 2012-12 (actual). Results posted on 2014-05-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure
Condition
Chronic Renal Insufficiency
Condition
Diabete Mellitus
Condition
Congestive Heart Failure
Intervention (Drug)
GE-145
Lead sponsor
GE Healthcare (class: industry)
Collaborator
i3 Statprobe (class: industry)
Collaborator
Medpace, Inc. (class: industry)
Collaborator
Biomedical Systems (class: industry)
Collaborator
Rules-Based Medicine, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01252810
Content hash
f48bfd7e3db3e335a6c41bdb69202baf8a14bca6e3e5667e254eb115901c67b8